期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
The Prevalence and Levels of Anti-HEV IgG in the Population of Jiangsu Province, China
1
作者 Xin Yao Ting Wu +7 位作者 Cheng Zhou Yi-min Li Feng-cai Zhu Qiang Yan Wei-jin Huang Chuan Ji Zheng-lun Liang Jun-zhi Wang 《国际感染病学(电子版)》 CAS 2013年第4期176-182,共7页
Objective To investigate the prevalence and levels of anti-HEV IgG in the population of Jiangsu Province.Methods Total of 2 656 samples from Qindong and 11 463 samples from Anfeng were colleted.The antiHEV antibody wa... Objective To investigate the prevalence and levels of anti-HEV IgG in the population of Jiangsu Province.Methods Total of 2 656 samples from Qindong and 11 463 samples from Anfeng were colleted.The antiHEV antibody was qualitatively and quantitatively detected using ELISA kits and the references had been established.Results The positive rates of anti-HEV IgG in male and female were 55.6%and 40.1%,respectively.The positive rate of anti-HEV IgM in male and female were both 3.4%.In opposite to anti-HEV IgG,the positive rate of anti-HEV IgM in Anfeng was significant higher than that in Qindong.The mean anti-HEV IgG titers for6 age groups were 0.94,0.92,1.07,1.46,1.27,1.19 and 0.68,1.31,1.08,1.14,1.31,1.68 IU/ml,in Qindong and Anfeng region,respectively.The positive rate of anti-HEV IgG tended to increase with age and the titer of antiHEV IgG was associated with age(R>0.90).Conclusions The results in this study showed that HEV was widely prevalent in both Qindong and Anfeng of Jiansu Province and the prevalence and the anti-HEV IgG titer were associated with gender and age. 展开更多
关键词 Hepatitis E virus Quantitation of anti-HEV IgG IMMUNOASSAY
下载PDF
一种可快速、持久且广谱保护新冠病毒感染的鼻喷减毒流感病毒载体新冠病毒疫苗 被引量:19
2
作者 陈俊煜 王培 +33 位作者 袁伦志 张良 张丽敏 赵慧 陈聪洁 王熹婧 韩金乐 陈耀德 贾继宗 卢珍 洪俊平 陆梓涔 王倩 陈日荣 戚若垚 马建 周明 于欢 庄春兰 刘晓辉 韩强远 王国松 苏迎盈 袁权 程通 吴婷 叶祥忠 张天英 李长贵 张军 朱华晨 陈毅歆 陈鸿霖 夏宁邵 《Science Bulletin》 SCIE EI CSCD 2022年第13期1372-1387,M0004,共17页
肌注式新冠病毒疫苗在呼吸道局部诱导的免疫应答较有限,不能高效阻止新冠病毒入侵呼吸道细胞.为此,该研究利用双重减毒的流感病毒载体(CA4-d NS1)开发出一种携带新冠病毒RBD基因的可经鼻腔喷雾方式接种的新冠病毒疫苗CA4-dNS1-nCoV-RBD... 肌注式新冠病毒疫苗在呼吸道局部诱导的免疫应答较有限,不能高效阻止新冠病毒入侵呼吸道细胞.为此,该研究利用双重减毒的流感病毒载体(CA4-d NS1)开发出一种携带新冠病毒RBD基因的可经鼻腔喷雾方式接种的新冠病毒疫苗CA4-dNS1-nCoV-RBD(简称dNS1-RBD).该疫苗在重症新冠肺炎仓鼠模型中表现出良好的保护效果,鼻喷接种1天后即可快速起效,两剂次鼻喷接种后可提供9个月以上的长效保护,表现为疫苗组仓鼠的体重未见明显下降,肺组织病理无明显损伤.该疫苗对Omicron等各种新冠病毒关切突变株均有广谱作用.另外,小鼠实验显示该疫苗还可广谱保护H1N1和H5N1流感病毒感染.该疫苗的保护机制涉及呼吸道局部的先天免疫应答、特异性T细胞应答、粘膜Ig A抗体应答和体液Ig G抗体应答等.总之,该研究表明快速、持久且广谱的鼻喷流感载体新冠病毒疫苗可与现有肌注式新冠病毒疫苗形成互补,共同抗击新冠疫情. 展开更多
关键词 病毒疫苗 流感病毒 减毒 病毒感染 免疫应答 H1N1 明显损伤 病毒入侵
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部